Parkinson's disease

Parkinson's disease is a chronic, progressive neurodegenerative disorder of the central nervous system. It is the second most common neurodegenerative disease after Alzheimer's disease and is most often diagnosed in older adults. Its defining feature is the death of dopamine-producing neurons in the substantia nigra, which reduces dopamine signalling in the basal ganglia and produces the characteristic motor problems of slowed movement, resting tremor, rigidity and postural instability. Many patients also develop non-motor symptoms such as loss of smell, sleep disturbance, constipation, depression and, in later stages, dementia. Pathologically, the disease belongs to the synucleinopathies, in which misfolded protein aggregates of alpha-synuclein form Lewy bodies inside affected cells.

The disease matters because it is common, disabling and, at present, not curable. Symptomatic treatments such as levodopa have transformed daily life for many patients since the 1960s, but no approved therapy has yet been shown to slow the underlying neurodegeneration. For this reason, research now focuses on early diagnosis, biomarkers, the spread of pathological protein through the brain, genetic and environmental risk factors, and disease-modifying drugs and cell-based therapies.

This entry first defines the disease and describes its clinical picture and neuropathology, then explains the molecular biology of alpha-synuclein and the dopamine circuits involved, followed by genetic and environmental risk factors and epidemiology. It next covers diagnosis, disease staging, symptomatic and advanced treatments, and the state of disease-modifying research. It closes with the history of discovery, research models, public health and social burden, and unresolved questions.

Definition and classification

Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by a motor syndrome associated with loss of dopamine-producing neurons in the substantia nigra, together with substantial non-motor manifestations. Neuropathologically, it is classified as a synucleinopathy: a disorder associated with abnormal accumulation of the protein alpha-synuclein. It is the most frequent disease in this group, which also includes dementia with Lewy bodies, multiple system atrophy and pure autonomic failure. In typical PD, alpha-synuclein accumulates in neuronal inclusions called Lewy bodies and in affected neuronal processes called Lewy neurites. This pathological classification describes its relationship to other diseases; it is distinct from the clinical classification based on symptoms and examination. (ninds.nih.gov)

Parkinsonism is a syndrome, not a synonym for Parkinson’s disease. The 2015 International Parkinson and Movement Disorder Society criteria, developed by Ronald B. Postuma and colleagues, define motor parkinsonism as bradykinesia—slowness of movement—combined with resting tremor, rigidity, or both. Consequently, tremor alone does not establish parkinsonism, and tremor is not required when bradykinesia and rigidity are present. Postural instability, although an important clinical feature, is not required by this definition. Once parkinsonism has been identified, its cause must be classified separately. PD is its most common cause, but the same broad motor syndrome can result from several distinct degenerative diseases or from acquired injury to the nervous system. (pubmed.ncbi.nlm.nih.gov)

The term idiopathic Parkinson’s disease conventionally denotes PD without an identified specific cause, distinguishing it from secondary parkinsonism; recognized inherited forms are also classified within PD. Atypical degenerative parkinsonism, sometimes called “Parkinson-plus” syndromes, includes multiple system atrophy, progressive supranuclear palsy and corticobasal degeneration. These are separate diseases rather than simply unusually severe forms of PD. Their pathological classifications also differ: multiple system atrophy is a synucleinopathy dominated by inclusions in oligodendrocytes, a type of glial cell, whereas progressive supranuclear palsy and corticobasal degeneration are tauopathies. Secondary parkinsonism, by contrast, can arise from medicines, vascular lesions, toxins or other identifiable insults; examples include exposure to metoclopramide, cerebrovascular damage and the neurotoxin MPTP. (pmc.ncbi.nlm.nih.gov)

Lewy body disease is a collective pathological term encompassing PD, Parkinson’s disease dementia and dementia with Lewy bodies, reflecting their shared neuronal alpha-synuclein pathology. It should be distinguished from Lewy body dementia, the clinical umbrella specifically covering Parkinson’s disease dementia and dementia with Lewy bodies. Their conventional separation depends on timing: dementia occurring before, concurrently with, or within one year of parkinsonism is classified as dementia with Lewy bodies; dementia developing in established PD is classified as Parkinson’s disease dementia. The 2017 DLB Consortium report led by Ian G. McKeith retained this one-year convention as a practical clinical boundary, not a demonstrated biological division. Multiple system atrophy belongs to the broader synucleinopathy group but is not ordinarily grouped among Lewy body diseases because its defining inclusions are predominantly glial. (pmc.ncbi.nlm.nih.gov)

PD is classified as a movement disorder because its clinically defined motor syndrome remains central to diagnosis. This designation does not imply that degeneration is confined to movement-controlling pathways. Disturbances of smell, sleep, autonomic function, mood and cognition form part of the disease, and some can precede recognizable parkinsonism. For example, constipation, loss of smell and REM sleep behaviour disorder may occur before motor onset, while depression and cognitive impairment can contribute substantially to disability. The 2015 diagnostic framework therefore recognizes non-motor features while retaining motor parkinsonism as the core of clinically manifest PD. (ninds.nih.gov)

Clinical features: motor symptoms

The four cardinal motor signs are bradykinesia, resting tremor, rigidity and postural instability, but they need not appear together. Motor symptoms usually begin gradually on one side—for example, tremor in one hand or reduced movement of one arm—and commonly remain more pronounced on that side after becoming bilateral. Early changes can include difficulty rising from a chair, cramped handwriting or reduced facial animation. Bradykinesia is the essential motor feature: the 2015 International Parkinson and Movement Disorder Society criteria define motor parkinsonism as bradykinesia combined with resting tremor, rigidity, or both, rather than requiring all four cardinal signs. (nia.nih.gov)

Bradykinesia involves slowness together with a progressive reduction in movement amplitude or speed during repetitive actions. During examination, finger tapping, repeated hand opening and closing, or foot tapping may become smaller, slower or interrupted. This distinguishes parkinsonian bradykinesia from slowness alone. Its everyday manifestations include prolonged washing and dressing, reduced spontaneous movement and fewer facial expressions, termed hypomimia or “masked face.” Micrographia describes abnormally small, cramped handwriting; letters may become progressively smaller across a line, reflecting difficulty maintaining the scale of sequential movements. (file.medtrib.cn)

Resting tremor is a rhythmic oscillation most evident when the affected limb is relaxed and supported. The characteristic frequency is approximately 4–6 Hz, and a hand tremor may resemble rolling a pill between the thumb and index finger. It often diminishes during purposeful movement and disappears during sleep; some patients never develop tremor. Rigidity, by contrast, is increased resistance when an examiner passively moves a joint. Sustained resistance is described as “lead-pipe” rigidity, whereas resistance interrupted by rhythmic catches is termed “cogwheel” rigidity. Rigidity may be experienced as stiffness or aching rather than recognized as an abnormality of muscle tone. (file.medtrib.cn)

Postural instability concerns impaired balance and corrective postural responses, not simply a stooped posture. It generally becomes prominent later than the other cardinal signs. In the clinical pull test, a brief backward displacement at the shoulders tests whether compensatory steps restore balance; inadequate recovery can lead to a backward fall. Recurrent falls from impaired balance within the first three years of motor onset are a diagnostic warning sign for an alternative parkinsonian disorder, rather than an obligatory early feature of Parkinson’s disease. (file.medtrib.cn)

Walking may show reduced arm swing, short shuffling steps and forward flexion of the trunk. Festination is a pattern of increasingly rapid, short steps with difficulty slowing or stopping. Freezing of gait is distinct from continuous slowness: forward progression briefly becomes markedly reduced or absent despite the intention to walk. Episodes commonly occur when initiating walking, turning or passing through doorways. In a 2023 survey of 171 people with Parkinson’s disease who already experienced freezing, 97.7% reported freezing at gait initiation, 88.9% during turning and 69.0% at doorways; these figures describe triggers within a selected freezing population, not prevalence among all patients. (ninds.nih.gov)

Motor presentations are often described as tremor-dominant or postural-instability and gait-difficulty (PIGD) predominant, with an intermediate group. These labels express the relative balance of symptoms rather than fixed disease categories. In a 2016 Parkinson’s Progression Markers Initiative analysis by Tanya Simuni and colleagues, 320 initially untreated participants with one-year classification data included 228 tremor-dominant, 56 PIGD and 36 indeterminate cases at baseline. By 12 months, 39% of the PIGD group and 18% of the tremor-dominant group had changed classification. A 2019 analysis also demonstrated shifts with disease progression and medication state, showing why motor subtype descriptions depend on when and under what conditions symptoms are assessed. (pubmed.ncbi.nlm.nih.gov)

Clinical features: non-motor symptoms

Reduced smell sensitivity (hyposmia), constipation, mood disturbances and sleep abnormalities can precede the characteristic motor symptoms by years. In the ONSET PD study, published in 2015, 109 newly diagnosed, untreated patients and 107 controls were questioned about symptom timing. Patients frequently recalled constipation and dream-enactment behaviour more than ten years before motor onset, whereas smell loss, fatigue, pain and mood disturbances were commonly reported within the preceding two to ten years. These were retrospective reports, rather than prospective measurements of onset. Hyposmia may involve difficulty detecting or identifying odours; it is common in early disease but is not specific to Parkinson's disease. (pubmed.ncbi.nlm.nih.gov)

Sleep disturbances include fragmented sleep, insomnia, excessive daytime sleepiness and REM sleep behaviour disorder (RBD). In RBD, the normal suppression of skeletal-muscle activity during rapid-eye-movement sleep is lost, allowing dream enactment through shouting, punching or kicking, sometimes causing injury. It differs from ordinary vivid dreaming and can precede motor disease by more than a decade. Daytime sleepiness may occur alongside disrupted night-time sleep, and some patients experience sudden episodes of sleep; medication can also contribute to sleep-related symptoms. RBD is associated with several neurodegenerative disorders, rather than exclusively with Parkinson's disease. (pubmed.ncbi.nlm.nih.gov)

Autonomic dysfunction affects gastrointestinal, cardiovascular, urinary, sexual and thermoregulatory functions. Constipation, urinary urgency or nocturia, sexual dysfunction and abnormal sweating can occur at different disease stages. Orthostatic hypotension produces a fall in blood pressure on standing, potentially causing lightheadedness, blurred vision, fainting or falls. The conventional sustained-drop criterion is at least 20 mmHg systolic or 10 mmHg diastolic within three minutes of standing. These manifestations reflect impaired automatic regulation of bodily functions, although sexual symptoms may also be influenced by depression and medication. They are distinct from the excessive sexual behaviour associated with some dopaminergic treatments. (pubmed.ncbi.nlm.nih.gov)

Depression, anxiety and apathy can occur early, including before dopaminergic treatment. Apathy denotes reduced motivation and initiation of activity and can occur without depressed mood. In a 2015 Parkinson's Progression Markers Initiative analysis led by Daniel Weintraub, 423 early, untreated patients were compared with 196 healthy controls: 14% of patients, versus 7% of controls, met the study's threshold for clinically significant depressive symptoms, and anxiety and apathy were also more prominent in patients. Psychotic symptoms were uncommon in this untreated cohort, affecting 3%. Hallucinations and delusions may nevertheless occur during the disease, and antiparkinsonian medicines can contribute to their emergence. (pubmed.ncbi.nlm.nih.gov)

Impulse-control disorders include compulsive gambling, buying, sexual behaviour and binge eating. These are particularly associated with dopamine-agonist treatment and should not be treated as inevitable consequences of the underlying disease. Weintraub and colleagues' 2010 cross-sectional study of 3,090 treated patients at 46 centres in the United States and Canada identified at least one such disorder in 13.6%. Prevalence was 17.1% among dopamine-agonist users and 6.9% among patients not taking an agonist. Related medication-associated behaviours include repetitive, purposeless activity, termed punding, and compulsive overuse of dopaminergic medication, termed dopamine dysregulation syndrome. (pubmed.ncbi.nlm.nih.gov)

Pain and fatigue are also prominent in early disease. Pain may accompany muscle rigidity, cramps or abnormal posture; fatigue manifests as persistent tiredness or loss of energy and can overlap with depression, sleep disturbance and medication effects. A 2015 study of 769 patients within 3.5 years of diagnosis found that pain and fatigue each affected more than half of participants. Cognitive changes can involve attention, planning, memory and visuospatial judgement without necessarily constituting dementia. In the early untreated cohort studied by Weintraub and colleagues, 22% screened positive for cognitive impairment on the Montreal Cognitive Assessment, but only 9% met the study's more detailed neuropsychological criteria for impairment at the mild-cognitive-impairment level, illustrating the importance of distinguishing screening results from fuller assessment. (ninds.nih.gov)

Neuropathology and the dopaminergic system

The characteristic neuronal loss affects the pars compacta of the substantia nigra, a midbrain region whose pigmented neurons supply dopamine to the striatum through the nigrostriatal pathway. Degeneration is uneven: ventrolateral nigral neurons are particularly vulnerable, whereas some dorsal populations are relatively preserved. Loss of neuromelanin-containing neurons produces visible pallor of the substantia nigra at autopsy. Their degeneration, together with loss or dysfunction of their axons and terminals, reduces dopamine availability in the striatum, especially the motor-associated putamen. Consequently, measurements of surviving cell bodies, striatal innervation and dopamine content describe related but distinct aspects of the lesion; they cannot be treated as interchangeable measures of disease severity. (pubmed.ncbi.nlm.nih.gov)

Lewy bodies are abnormal inclusions within neuronal cell bodies, while Lewy neurites are pathological accumulations within neuronal processes. Classical brainstem Lewy bodies have a dense, eosinophilic core surrounded by a paler halo; cortical inclusions are often less sharply defined. Their major filamentous component is α-synuclein, identified in Lewy bodies by Maria Grazia Spillantini and colleagues in 1997 and demonstrated in extracted filaments in 1998. They also contain ubiquitin, cytoskeletal proteins and other cellular constituents. In 2019, Sarah Shahmoradian and colleagues used correlative light and electron microscopy to show that human Lewy pathology contains crowded lipid membranes, vesicles and abnormal organelles, with filaments identifiable in many, but not all, examined inclusions. Lewy bodies are therefore structurally complex deposits rather than simply compact masses of one protein. (pmc.ncbi.nlm.nih.gov)

Lewy pathology extends beyond the nigrostriatal system. Heiko Braak, Kelly Del Tredici and colleagues proposed a six-stage anatomical scheme in 2003, based on postmortem specimens from individuals with incidental pathology and clinically diagnosed disease. Stages 1–2 describe involvement of olfactory structures and lower brainstem nuclei, including the dorsal motor nucleus of the vagus, followed by pontine regions such as the locus coeruleus. Stages 3–4 include the substantia nigra and subsequently temporal mesocortical and limbic regions; stages 5–6 involve progressively broader areas of the cerebral cortex. This describes a proposed sequence of regional involvement, not six directly observed time points in an individual patient. The distribution also makes clear why nigral dopamine depletion alone cannot account for the entire clinical syndrome. (pubmed.ncbi.nlm.nih.gov)

Not all brains conform to a single ascending sequence. Thomas Beach and colleagues’ 2009 unified staging system accommodates olfactory-bulb-only pathology, brainstem-predominant and limbic-predominant patterns, combined brainstem–limbic involvement, and neocortical disease. Such alternatives distinguish the anatomical distribution of inclusions from clinical staging. Lewy pathology can be present in individuals without diagnosed parkinsonism, and its regional extent is not equivalent to the amount of neuronal loss or the severity of motor impairment. Cross-sectional autopsy findings support staging frameworks but do not, by themselves, establish that pathology travelled between regions in a particular order. (pmc.ncbi.nlm.nih.gov)

Substantial degeneration precedes recognizable motor symptoms, but there is no universal numerical threshold. Age-adjusted postmortem estimates place nigral dopaminergic neuronal loss near 30% at motor onset; striatal dopamine depletion is generally greater, reflecting the distinction between cell-body survival and terminal function. A compensatory reserve helps explain this discrepancy. Surviving terminals can alter dopamine synthesis and handling, partially maintaining transmission despite declining innervation. In a 2000 positron emission tomography study of 35 patients and 16 controls, C. S. Lee and colleagues compared markers of dopamine synthesis, vesicular storage and dopamine transporters. Their results supported increased aromatic L-amino acid decarboxylase activity and reduced dopamine-transporter availability—adaptations that could enhance dopamine production and limit its removal from extracellular space. These responses also mean that an imaging signal need not decline in direct proportion to neuronal number. (ncbi.nlm.nih.gov)

Dopamine and basal ganglia circuits

Dopamine modulates the selection, initiation and learning of actions within the basal ganglia, rather than directly commanding muscle contraction. Nigrostriatal projections deliver dopamine to the striatum, where it changes how neurons respond to input from the cerebral cortex. Its role extends beyond immediate movement: in 2005, Alexis Faure and colleagues showed that selective nigrostriatal dopamine depletion in rats disrupted the development of stimulus–response habits after extended training. Dopamine also supplies learning signals about reward. Wolfram Schultz, Peter Dayan and P. Read Montague’s 1997 account linked brief changes in dopamine-neuron firing to reward-prediction errors: unexpected rewards evoke increased firing, whereas omission of an expected reward produces a decrease. These signals help adjust which actions are subsequently selected. (ncbi.nlm.nih.gov)

The classical motor-circuit model distinguishes two routes from striatal spiny projection neurons to basal-ganglia output nuclei. In the direct pathway, inhibitory striatal neurons project to the internal globus pallidus and substantia nigra pars reticulata. These output nuclei normally inhibit thalamic and brainstem targets; inhibiting them therefore disinhibits downstream motor circuits. In the indirect pathway, striatal neurons inhibit the external globus pallidus, reducing its inhibition of the subthalamic nucleus. The subthalamic nucleus then provides stronger excitatory input to basal-ganglia output nuclei, increasing inhibition of downstream targets. Dopamine generally promotes direct-pathway activity through D1 receptors and restrains indirect-pathway activity through D2 receptors. Its loss consequently shifts this model toward excessive inhibitory output, contributing to difficulty initiating and scaling movements. (ncbi.nlm.nih.gov)

This account is useful but does not fully explain bradykinesia or rigidity through average firing rates alone. In 2010, Alexxai Kravitz and colleagues used optogenetic stimulation in mice to show that activating indirect-pathway neurons suppressed movement, while activating direct-pathway neurons relieved freezing, bradykinesia and impaired movement initiation in a dopamine-depletion model. However, Guohong Cui and colleagues demonstrated in 2013 that both pathways became active before voluntary actions, challenging their interpretation as mutually exclusive “go” and “stop” systems. Human recordings also implicate abnormal synchronization: Andrea Kühn and colleagues’ 2006 study of nine patients found that levodopa-induced reductions in subthalamic oscillatory activity within the 8–35 Hz band correlated with improvement in akinesia–rigidity scores ($r=0.835$), but not tremor. Thus, disturbed timing and coordination accompany the imbalance in pathway activity. (nature.com)

Receptor selectivity explains important differences between dopamine-replacement strategies. D1 receptors predominantly characterize direct-pathway projection neurons, whereas D2 receptors characterize indirect-pathway neurons. Levodopa crosses the blood–brain barrier and is converted into dopamine, allowing stimulation of multiple receptor subtypes; dopamine itself does not cross this barrier sufficiently for the same purpose. Dopamine agonists instead stimulate receptors directly. Pramipexole, for example, acts at the D2 receptor family, which includes D2, D3 and D4, and has higher in-vitro affinity for D3 than for D2 or D4. This affinity should not be equated with an established D3-specific explanation of motor benefit: its prescribing information explicitly identifies the relevance of D3 binding in Parkinson’s disease as unknown. (ncbi.nlm.nih.gov)

Non-dopaminergic degeneration changes the wider networks in which these motor loops operate. The noradrenergic locus coeruleus is affected, and a study published in 2018 combined noradrenaline-transporter positron emission tomography with neuromelanin-sensitive MRI in 30 patients and 12 controls. Reduced noradrenergic markers were associated with REM sleep behaviour disorder, poorer cognitive performance and orthostatic hypotension. These associations support a contribution from noradrenergic dysfunction without establishing a single-transmitter cause for each symptom. (pubmed.ncbi.nlm.nih.gov)

The serotonergic system, originating in brainstem raphe nuclei, is also disrupted. A 2015 imaging study involving 345 untreated patients with early Parkinson’s disease found reduced raphe serotonin-transporter availability relative to controls. Symptom relationships are regionally heterogeneous: Nicola Pavese and colleagues’ 2010 PET study associated fatigue with lower transporter binding in striatal and limbic regions, despite similar striatal dopamine-storage measurements between fatigued and non-fatigued groups. A separate 2010 study of 34 patients associated depressive symptoms with relatively higher transporter binding in selected raphe and limbic regions. These findings distinguish altered serotonergic regulation from a uniform deficiency and help explain why dopamine replacement does not address every manifestation of the disease. (pubmed.ncbi.nlm.nih.gov)

Alpha-synuclein biology

Alpha-synuclein is a 140-amino-acid protein concentrated at presynaptic terminals, where its interaction with membranes links it to synaptic function. Its sequence contains three principal regions: an N-terminal membrane-binding region, approximately residues 1–60; a hydrophobic central region, residues 61–95, known as the non-amyloid-β component (NAC); and an acidic C-terminal tail, residues 96–140. The soluble protein is largely disordered, whereas membrane binding induces an alpha-helical conformation in its N-terminal region. The NAC region contributes strongly to aggregation, while the C-terminal tail influences solubility and molecular interactions. These properties allow the same molecule to participate in normal membrane-associated processes and, under different conditions, assemble into pathological aggregates. (pmc.ncbi.nlm.nih.gov)

Proposed physiological functions include organizing synaptic vesicles and maintaining the machinery responsible for neurotransmitter release, rather than simply increasing or decreasing release in all circumstances. In 2010, Jacqueline Burré and colleagues demonstrated that alpha-synuclein promotes assembly of SNARE complexes, which bring vesicle and plasma membranes together for fusion. This activity involves simultaneous binding to phospholipids through its N terminus and to the vesicular protein synaptobrevin-2 through its C terminus. Experiments published in 2014 further showed that membrane-bound alpha-synuclein forms higher-order multimers capable of supporting SNARE assembly. Such physiological assemblies must be distinguished from disease-associated oligomers: association between several alpha-synuclein molecules is not, by itself, evidence of pathological protein folding. (cbdm.hms.harvard.edu)

Pathological aggregation produces heterogeneous oligomers—assemblies containing relatively few molecules—and longer amyloid fibrils with ordered beta-sheet-rich structures. Their biological effects depend on conformation as well as size. In 2017, Giuliana Fusco and colleagues identified structural features that distinguish membrane-disrupting oligomers: a lipophilic region promotes membrane association, while a structured region inserts into the lipid bilayer and compromises its integrity. This provides an experimental mechanism for oligomer toxicity, but does not establish that every oligomer is harmful or that oligomers alone account for neuronal degeneration. Fibrils are also biologically active: they can seed aggregation of endogenous alpha-synuclein and initiate degeneration in animal experiments. Thus, “toxic oligomer” and “inert fibril” are not universally applicable categories. (pubmed.ncbi.nlm.nih.gov)

Evidence for propagation between neurons combines human transplantation observations with experimental seeding studies. In 2008, Jia-Yi Li and colleagues reported alpha-synuclein-positive Lewy bodies in transplanted fetal dopaminergic neurons that had survived for 11–16 years in two people with Parkinson’s disease. This suggested that the host environment could transmit or induce pathology in initially unaffected grafts, although the observation alone did not identify the transfer mechanism. In 2012, Kelvin Luk and colleagues injected synthetic preformed alpha-synuclein fibrils into the striatum of non-transgenic mice. Endogenous protein subsequently formed Lewy-like inclusions in anatomically connected regions, followed by loss of substantia nigra dopaminergic neurons and motor impairment. These findings support a templated, “prion-like” mechanism in which an abnormal assembly recruits additional protein into an abnormal conformation; the experimental mechanism should not be equated with demonstrated person-to-person transmission. (pubmed.ncbi.nlm.nih.gov)

Post-translational modifications can alter alpha-synuclein’s aggregation behaviour. Hideo Fujiwara and colleagues showed in 2002 that serine 129 is extensively phosphorylated in synucleinopathy deposits; approximately 90% of deposited alpha-synuclein carries this modification, compared with less than 5% in healthy brain. Nevertheless, this enrichment does not establish phosphorylation as the initiating event. A 2022 experimental study found that serine-129 phosphorylation occurred after initial deposition and inhibited seeded fibril formation and toxicity under the conditions tested. Proteolytic processing provides another influence: studies of C-terminally truncated alpha-synuclein show accelerated fibril formation, consistent with removal of the acidic tail reducing constraints on aggregation. Phosphorylation and truncation therefore have distinct, context-dependent effects rather than acting as interchangeable markers of protein damage. (pubmed.ncbi.nlm.nih.gov)

Mechanisms beyond protein aggregation

Mitochondrial dysfunction can compromise neuronal energy production and increase oxidative damage. In 1990, Anthony Schapira and colleagues examined postmortem substantia nigra tissue from nine patients and nine matched controls, finding reduced activity of respiratory-chain complex I despite similar mitochondrial mass. Complex I transfers electrons from NADH into the respiratory chain; its impairment can disrupt oxidative phosphorylation, which supplies ATP, and promote reactive oxygen species. A mechanistic connection to dopamine metabolism emerged from Lena Burbulla and colleagues’ 2017 experiments in patient-derived dopaminergic neurons: mitochondrial oxidant stress promoted dopamine oxidation, followed by reduced glucocerebrosidase activity, lysosomal dysfunction and α-synuclein accumulation. This experimentally observed sequence links energy metabolism, oxidative injury and defective protein clearance rather than treating them as independent abnormalities. (pubmed.ncbi.nlm.nih.gov)

Mitochondrial quality control also depends on autophagy, the delivery of cellular material to lysosomes for degradation. In experimental systems, loss of mitochondrial membrane potential causes PINK1 to accumulate at the mitochondrial surface and recruit parkin, promoting selective disposal of damaged mitochondria, termed mitophagy. Disruption of this pathway can allow dysfunctional organelles to persist. Lysosomes also remove soluble proteins through chaperone-mediated autophagy, in which selected substrates cross the lysosomal membrane. Ana Maria Cuervo and colleagues showed in 2004 that the A30P and A53T α-synuclein variants bound to the uptake machinery but blocked degradation of themselves and other substrates. Thus, defective clearance can increase the protein burden, while abnormal proteins can further inhibit clearance. (pubmed.ncbi.nlm.nih.gov)

The lysosomal enzyme glucocerebrosidase provides another connection between lipid metabolism and protein disposal. It normally breaks down glucosylceramide; reduced activity changes the lysosomal lipid environment and can impair protein degradation. In 2011, Joseph Mazzulli and colleagues demonstrated in cultured neurons, including human induced-pluripotent-stem-cell-derived neurons, that glucocerebrosidase loss caused α-synuclein accumulation and aggregation-dependent toxicity. Accumulating α-synuclein, in turn, inhibited normal glucocerebrosidase function, establishing a proposed bidirectional pathogenic loop. These findings concern cellular mechanisms; the inheritance and risk associated with the enzyme’s encoding gene, GBA1, are separate questions. (pmc.ncbi.nlm.nih.gov)

Neuroinflammation involves both resident brain immune cells and the peripheral immune system. Microglia, a type of glial cell, respond to neuronal injury and extracellular α-synuclein. Richard Gordon and colleagues reported in 2018 that fibrillar α-synuclein activated the microglial NLRP3 inflammasome, a protein complex that activates caspase-1 and promotes release of the cytokine interleukin-1β. Inflammasome-related proteins were elevated in patient substantia nigra tissue, and experimental inhibition reduced degeneration in rodent models. Peripheral adaptive immunity is implicated by David Sulzer and colleagues’ 2017 study of 67 patients and 36 controls: α-synuclein peptides elicited responses from patient T cells, including CD4-positive and CD8-positive populations. These observations demonstrate immune recognition and inflammatory activity, but do not establish that an autoimmune response initiates the disease. (pubmed.ncbi.nlm.nih.gov)

The gut–brain axis hypothesis proposes that intestinal conditions can influence neurodegeneration through microbial metabolites, immune signalling and neural connections. In 2016, Timothy Sampson and colleagues found that germ-free mice overexpressing human α-synuclein had less microglial activation and fewer motor deficits than colonized counterparts; microbiota transferred from patients produced greater motor impairment than microbiota from healthy donors in this model. A proposed anatomical route involves abnormal α-synuclein arising in enteric neurons and travelling through the vagus nerve to the brainstem. Sangjune Kim and colleagues tested this route in 2019 by injecting preformed α-synuclein fibrils into the mouse gastrointestinal tract. Pathology subsequently reached the brain, whereas truncal vagotomy prevented the observed spread and associated degeneration. These experiments establish biological plausibility in models, not that intestinal initiation occurs in every human case or that a particular microbial community causes Parkinson’s disease. (pmc.ncbi.nlm.nih.gov)

Genetics and inherited forms

Rare pathogenic gene variants can produce Parkinson's disease through recognizable inheritance patterns, whereas common variants generally modify susceptibility rather than determine whether disease occurs. SNCA and LRRK2 are associated with autosomal dominant forms: one altered copy can be sufficient, although penetrance—the proportion of carriers who develop disease—varies. In 1997, Mihael Polymeropoulos and colleagues identified an SNCA mutation in an Italian kindred and three Greek families with dominantly inherited Parkinson's disease. SNCA encodes alpha-synuclein; pathogenic changes include sequence variants and duplication or triplication of the gene. Andrew Singleton and colleagues reported an SNCA triplication in 2003, establishing that increased dosage of an otherwise normal gene can cause disease. LRRK2 encodes a kinase involved in intracellular trafficking; its p.Gly2019Ser variant is a prominent example of an age-dependent, incompletely penetrant dominant variant. A carrier can therefore transmit the variant without ever developing Parkinson's disease. (ncbi.nlm.nih.gov)

PRKN, formerly called PARK2, and PINK1 cause autosomal recessive forms, usually requiring pathogenic variants in both gene copies. These may be identical variants or two different variants, one on each parental copy. Recessive inheritance helps explain affected siblings born to clinically unaffected parents and cases without an obvious family history. PRKN-related disease commonly begins before age 40, with a reported median onset of 31 years. Compared with typical late-onset disease, its course is often slowly progressive, lower-limb dystonia can be an early feature, and cognition is usually relatively preserved. Levodopa responsiveness is pronounced, but treatment-associated motor fluctuations and dyskinesias are common. PINK1-related disease also typically has early onset. These genotype-associated patterns do not apply uniformly to all disease beginning before age 50, which includes both genetic and unexplained cases. (ncbi.nlm.nih.gov)

GBA1, historically termed GBA, differs from these straightforward Mendelian examples. It encodes the lysosomal enzyme glucocerebrosidase; pathogenic variants in both copies cause Gaucher disease, an autosomal recessive disorder. A single pathogenic copy increases Parkinson's disease susceptibility, but most heterozygous carriers do not develop it. Penetrance depends on the particular variant, age, ancestry and how carriers were recruited. Estimates summarized in GeneReviews range from approximately 10–15% by age 80 in Gaucher-family cohorts to 20–30% in Parkinson's cohorts, illustrating why a single risk estimate cannot represent every carrier. GBA1-associated Parkinson's disease is therefore distinguished from highly penetrant dominant disease, even though it can aggregate within families. (ncbi.nlm.nih.gov)

Common susceptibility variants are identified through genome-wide association studies, which compare variant frequencies across large groups. In a 2019 meta-analysis, Mike Nalls and colleagues examined 37,688 cases, 18,618 proxy cases identified through affected first-degree relatives, and approximately 1.4 million controls. They identified 90 independent significant risk signals across 78 genomic regions. Individual common variants generally have small effects; their combined contribution can be summarized in a polygenic risk score, but such a score is not a Mendelian diagnosis. The study estimated that its 90 signals accounted for 16–36% of heritable risk, depending on the assumed disease prevalence—not 16–36% of all cases. Its predominantly European-ancestry sample also limits direct extrapolation to other populations. (pmc.ncbi.nlm.nih.gov)

Genetic testing distinguishes pathogenic variants, susceptibility variants and variants of uncertain significance; these categories have different implications for relatives. Panels may require deletion-and-duplication analysis as well as sequencing, particularly for PRKN. Genetic counselling addresses incomplete penetrance, inheritance, uncertain results and the distinction between inheriting a variant and developing disease. In the North American PD GENEration study, reported in 2024, approximately 13% of 8,301 participants who had received results carried a reportable variant; the yield was approximately 9% among those without predefined high-risk features. Reportable findings included risk variants and therefore were not synonymous with confirmed monogenic disease. Research cohorts also follow carriers before motor onset: the Parkinson's Progression Markers Initiative's 2021 protocol included genetically at-risk participants and longitudinal clinical, imaging and biosample assessments, enabling investigation of which carriers develop disease and how early changes relate to subsequent progression. (ncbi.nlm.nih.gov)

Environmental and lifestyle risk factors

Advancing age is the strongest established risk factor for Parkinson’s disease, with most cases beginning after age 60. Men are affected more frequently than women, although the difference does not establish whether biological sex, occupational exposures or other influences account for the excess. These demographic associations coexist with substantial individual variation: neither older age nor an environmental exposure makes disease inevitable. In most patients, no single cause can be identified, and susceptibility is understood as involving both genetic and environmental factors. (ncbi.nlm.nih.gov)

Exposure to certain pesticides is among the better-supported environmental associations, but pesticides are chemically diverse and cannot be treated as a single exposure. In 2011, Caroline Tanner and colleagues reported results from the Farming and Movement Evaluation study, nested within the US Agricultural Health Study. Among 110 cases and 358 controls, reported use of rotenone and paraquat was associated with odds ratios of 2.5 for each compound; the respective 95% confidence intervals were 1.3–4.7 and 1.4–4.7. These chemicals provide different mechanistic examples: rotenone inhibits mitochondrial complex I, impairing energy production, whereas paraquat promotes oxidative stress. Such experimental mechanisms support biological plausibility but do not, by themselves, establish the effects of particular human exposure levels. Agricultural work, rural residence and well-water consumption are less specific exposure indicators, because they may combine pesticide contact with other occupational and geographical influences. (pubmed.ncbi.nlm.nih.gov)

Organic solvents, particularly trichloroethylene (TCE), have also been investigated. A 2023 study led by Samuel Goldman compared military personnel stationed for at least three months during 1975–1985 at Camp Lejeune, where drinking water was contaminated, with personnel at Camp Pendleton. Among veterans with available health data, Parkinson’s disease prevalence was 0.33% versus 0.21%; the adjusted odds ratio was 1.70 (95% confidence interval, 1.39–2.07). The several-decade interval between exposure and diagnosis is important for interpreting environmental risk. However, Camp Lejeune water contained multiple volatile organic compounds, and individual historical doses were not directly measured, limiting attribution of the association specifically to TCE. (pubmed.ncbi.nlm.nih.gov)

A history of traumatic brain injury has been associated with subsequent Parkinson’s disease. Raquel Gardner and colleagues’ 2018 study of 325,870 US veterans found adjusted hazard ratios of 1.56 after mild injury and 1.83 after moderate-to-severe injury, compared with no recorded injury. Absolute proportions diagnosed during follow-up were 0.47%, 0.75% and 0.31%, respectively. Other proposed factors have less consistent evidence. Air-pollution studies differ in their findings and exposure definitions, while dietary associations can depend on the food category examined: a 2017 analysis of two US cohorts found an association with low-fat dairy consumption but not with total dairy intake. These results do not establish that all head injuries, pollutants or dairy products confer equivalent risk. (pubmed.ncbi.nlm.nih.gov)

Coffee or caffeine consumption, cigarette smoking and physical activity show inverse associations in observational epidemiological studies. In a 2012 NIH–AARP cohort analysis involving 304,980 participants, the highest versus lowest caffeine-intake quintile had adjusted odds ratios of 0.75 in men and 0.60 in women. A 2023 analysis of the French E3N women’s cohort found 25% lower Parkinson’s disease incidence in the highest physical-activity quartile than in the lowest. Nevertheless, lower observed incidence is not equivalent to demonstrated prevention. The smoking association is especially difficult to interpret: Beate Ritz and colleagues’ 2014 Danish case-control study found that patients had reported greater ease of quitting, supporting the possibility that prediagnostic disease changes nicotine responsiveness and smoking behaviour. (pubmed.ncbi.nlm.nih.gov)

Causal interpretation is complicated by the long interval between biological disease onset and clinical diagnosis. Reduced activity or altered smoking behaviour may therefore be consequences of developing disease rather than causes of lower or higher risk. Retrospective exposure reports are vulnerable to recall error, while residential or occupational categories may poorly represent absorbed dose. Prospective studies, repeated exposure assessments and analyses excluding diagnoses shortly after exposure measurement help address these problems, but cannot eliminate unmeasured confounding. The E3N activity study, for example, used lagged analyses to reduce reverse causation; the Camp Lejeune study still faced uncertainty about individual solvent exposure and incomplete ascertainment outside available health records. (pubmed.ncbi.nlm.nih.gov)

Epidemiology and global burden

The epidemiology of Parkinson’s disease is strongly age-dependent, with prevalence—the proportion of people living with the disease—rising particularly sharply after age 60. A 2014 systematic review by Tamara Pringsheim and colleagues, combining 47 studies, estimated prevalence at 41 per 100,000 people aged 40–49, 107 at 50–59, 428 at 60–69, 1,087 at 70–79, and 1,903 above age 80. These pooled estimates describe different populations rather than the trajectory of a single cohort. Incidence, which measures newly diagnosed cases per unit of population and time, also increases with age. A North American study published in 2022, using five datasets principally from 2012, found age- and sex-standardized incidence ranging from 47 to 77 per 100,000 person-years among adults aged 45 or older, compared with 108–212 among those aged 65 or older. Incidence increased between ages 65–74 and 75–84 in every dataset, although trends above age 85 differed by ascertainment method. (pubmed.ncbi.nlm.nih.gov)

Early-onset, or young-onset, disease generally denotes symptom onset before age 50, although studies differ in their age thresholds and whether they classify cases by onset or diagnosis. It represents a small minority of the total burden: the Parkinson’s Foundation estimates that approximately 4% of people living with Parkinson’s disease in the United States have young-onset disease. A population-based investigation in seven Minnesota counties during 2010–2015 estimated incidence before age 50 at 0.81 per 100,000 person-years. Such estimates should not be confused with the proportion of patients currently younger than 50, because people with early-onset disease remain in that category as they age. (parkinson.org)

The Global Burden of Disease Study 2021 estimated approximately 11.77 million prevalent cases worldwide, with a 95% uncertainty interval of about 10.4–13.4 million, and approximately 1.34 million new cases during 2021. Within that modelling framework, prevalent cases increased from 3.15 million in 1990, a rise of approximately 274%. The increase was not solely demographic: age-standardized incidence rose from 11.24 to 15.63 per 100,000 between 1990 and 2021. Age-standardized rates apply a common population age distribution, allowing comparisons that are less affected by differences in population ageing. The estimated global age-standardized prevalence in 2021 was 138.63 per 100,000. (sciencedirect.com)

Burden estimates also incorporate premature death and non-fatal disability through disability-adjusted life years (DALYs). The World Health Organization reported that Parkinson’s disease accounted for 5.8 million DALYs and 329,000 deaths in 2019; the DALY total had increased by 81% since 2000. Geographic variation is substantial. Pringsheim’s meta-analysis found prevalence among people aged 70–79 of 1,601 per 100,000 in North America, Europe, and Australia, compared with 646 in Asia. However, comparisons depend on the period studied, diagnostic criteria, case-finding methods, and access to clinical services. The North American incidence study likewise found appreciable differences between administrative databases and specialist-confirmed cohorts, demonstrating that measured variation cannot automatically be attributed to biological or environmental differences. (who.int)

Population ageing increases case numbers by expanding the age groups with the highest disease frequency, while population growth enlarges the population at risk; prevalence is additionally affected by survival after diagnosis. A modelling study published in The BMJ in March 2025 projected 25.2 million people living with Parkinson’s disease worldwide in 2050, with a 95% uncertainty interval of 21.7–30.1 million, representing a 112% increase over 2021. Its decomposition attributed 89 percentage points of that increase to ageing, 20 to population growth, and 3 to changes in prevalence unrelated to those demographic shifts. The projected increase was greatest among people aged 80 or older, whose case numbers were expected to rise by 196%. These figures are conditional projections based on historical data and model assumptions, rather than observed future counts. (nature.com)

Diagnosis and biomarkers

Clinical diagnosis rests on the history, neurological examination, and exclusion of alternative causes of parkinsonism. The 2015 International Parkinson and Movement Disorder Society (MDS) criteria, developed by Ronald Postuma and colleagues, require bradykinesia together with rigidity or resting tremor before Parkinson’s disease can be considered. Bradykinesia includes slowness and progressive reduction in movement amplitude or speed during repeated actions. “Clinically established” disease requires no absolute exclusion criteria, at least two supportive features, and no red flags; “clinically probable” disease permits up to two red flags when counterbalanced by supportive features. A clear, substantial response to levodopa supports diagnosis, whereas absent response to high-dose levodopa despite moderately severe disease is an exclusion criterion. Early severe autonomic failure, recurrent falls, or rapid gait deterioration raise suspicion of alternative disorders. (med.upenn.edu)

Treatment response is interpreted longitudinally rather than as a definitive single-dose test; NICE guidance does not recommend acute levodopa or apomorphine challenges for differential diagnosis. Diagnostic uncertainty is greatest early in the course, before characteristic features of competing disorders emerge. A 2016 meta-analysis by Giovanni Rizzo and colleagues found pooled clinical diagnostic accuracy of 80.6% in 11 studies using neuropathological examination as the reference standard. Among movement-disorder specialists, estimated accuracy increased from 79.6% at initial assessment to 83.9% after follow-up. These estimates describe the included historical cohorts, rather than the performance of every contemporary diagnostic setting. (nice.org.uk)

Dopamine-transporter single-photon emission computed tomography (DAT-SPECT), commonly using $^{123}\mathrm{I}$-ioflupane, assesses presynaptic dopaminergic terminals in the striatum. It can help distinguish essential tremor from a degenerative parkinsonian syndrome when examination is inconclusive. Reduced uptake supports a dopaminergic deficit, but does not distinguish Parkinson’s disease from multiple system atrophy or progressive supranuclear palsy. Normal presynaptic dopaminergic imaging, when performed and appropriately interpreted, is an absolute exclusion criterion in the 2015 MDS framework; imaging is not mandatory for otherwise typical cases. Structural magnetic resonance imaging serves principally to investigate alternative causes or atypical parkinsonian syndromes, not to establish Parkinson’s disease itself. (ema.europa.eu)

Molecular biomarkers increasingly target pathological alpha-synuclein. Seed amplification assays exploit the ability of misfolded aggregates to induce aggregation of additional protein, amplifying a small seed into a detectable signal. In a 2023 Parkinson’s Progression Markers Initiative study, Andrew Siderowf, Luis Concha-Marambio, and colleagues examined cerebrospinal fluid from 1,123 participants. Sensitivity among 545 participants diagnosed with Parkinson’s disease was 87.7%, and specificity among 163 healthy controls was 96.3%. Positivity varied substantially: it reached 98.6% in sporadic disease with olfactory impairment, but was 67.5% in LRRK2-associated disease. Thus, a negative assay does not exclude all clinically diagnosed forms, and performance against healthy controls does not establish equivalent accuracy against every competing neurological disorder. (pmc.ncbi.nlm.nih.gov)

Peripheral tissue offers another route to detecting pathology. A blinded, multicentre study led by Christopher Gibbons, published in 2024, detected phosphorylated alpha-synuclein in skin biopsies from 89 of 96 participants with Parkinson’s disease (92.7%), compared with 4 of 120 controls (3.3%). Positivity was also frequent in multiple system atrophy, dementia with Lewy bodies, and pure autonomic failure, so detection indicates synuclein pathology rather than uniquely identifying Parkinson’s disease. Blood-based seed amplification is also under investigation: a 2024 study using a method focused on neuron-derived extracellular vesicles detected seeding activity in 8 of 13 participants with PRKN-associated disease, illustrating that assay method and sampled compartment can affect classification. (jamanetwork.com)

Before motor diagnostic criteria are met, prodromal assessment combines probabilistic evidence rather than relying on an isolated symptom. MDS research criteria introduced in 2015 and updated in 2019 combine age-related prior probability with likelihood ratios for markers such as olfactory loss, REM sleep behaviour disorder, autonomic abnormalities, and genetic risk; “probable prodromal” disease requires an estimated probability of at least 80%. These are research criteria, not a population-screening diagnosis. In the 2023 seed-amplification study, 44 of 51 selected participants with REM sleep behaviour disorder or hyposmia tested positive. Such findings demonstrate detection before conventional motor diagnosis, but a cross-sectional positive result does not specify whether or when an individual will develop clinical Parkinson’s disease. (med.stanford.edu)

Staging, progression and related disorders

The Hoehn and Yahr scale, introduced by Margaret Hoehn and Melvin Yahr in 1967, describes motor severity in five stages. Stage 1 denotes unilateral involvement; stage 2, bilateral involvement without impaired balance; and stage 3, postural instability with preserved physical independence. At stage 4, disability is severe, although standing or walking without assistance remains possible; at stage 5, the person is confined to a wheelchair or bed unless assisted. Modified versions add intermediate stages 1.5 and 2.5. These categories describe current function rather than a fixed timetable: the intervals between stages are unequal, and the scale does not adequately capture cognitive, autonomic or other non-motor disability. (movementdisorders.org)

More detailed longitudinal assessment uses the Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), whose revised form was validated in 2008 by Christopher Goetz and colleagues in 877 patients. Its four parts assess non-motor experiences of daily living, motor experiences of daily living, the motor examination, and motor complications. Items are rated from 0 to 4, with higher scores indicating greater impairment. Serial assessments can therefore distinguish worsening examination findings from increasing difficulty with everyday activities or treatment-related complications. The examination records medication status and whether the patient is “ON,” with symptomatic benefit, or “OFF,” with diminished benefit; comparisons made in different medication states can otherwise misrepresent progression. (bumc.bu.edu)

Over time, the initially sustained response to levodopa may become shorter and less predictable. “Wearing-off” means symptoms return before the next scheduled dose; other fluctuations include delayed benefit, dose failure and abrupt ON–OFF transitions. Progressive loss of dopaminergic nerve terminals reduces the capacity to buffer changes in dopamine availability, while intermittent drug delivery, variable absorption and altered striatal signalling also contribute. Dyskinesias are involuntary movements associated with treatment, occurring most commonly near peak levodopa benefit, but also during rising or falling drug effects. Their timing is highly variable: in the 141-patient CamPaIGN incident cohort, estimated cumulative incidence at five years was 54.3% for motor fluctuations and 14.5% for dyskinesias. A separate 2024 analysis of 3,343 patients associated motor complications with younger age at diagnosis, higher medication doses and greater dopaminergic responsiveness. (pmc.ncbi.nlm.nih.gov)

The transition to advanced disease is not defined by duration alone. One operational screening approach, the “5-2-1” criteria, identifies people taking at least five daily oral levodopa doses, experiencing at least two hours of OFF time daily, or having at least one hour of troublesome dyskinesia daily. Meeting any one threshold flags substantial treatment burden rather than establishing a complete clinical stage. In a 2020 study of 102 patients, those meeting these criteria had poorer quality of life, greater non-motor symptom burden and less independence in daily activities. Thus, motor complications and broader functional impairment provide complementary measures of advancement. (pubmed.ncbi.nlm.nih.gov)

Parkinson’s disease dementia denotes cognitive decline sufficient to interfere with everyday functioning in established Parkinson’s disease. The conventional “one-year rule” distinguishes it from dementia with Lewy bodies: dementia beginning before, concurrently with, or within one year of parkinsonism is classified as the latter, whereas dementia developing after more than one year of established motor disease is classified as Parkinson’s disease dementia. The 2017 consensus report led by Ian McKeith retained this practical boundary while acknowledging its arbitrary nature and the disorders’ biological overlap. Long-term risk estimates depend strongly on the population and assessment method. A 2024 study estimated ten-year dementia probabilities of 9% in 417 newly diagnosed research participants and 27% in 389 participants from a specialist clinical cohort; the latter estimate reached 50% at fifteen years. (pmc.ncbi.nlm.nih.gov)

Prognostic associations differ by outcome. In a prospective community-based cohort, poorer baseline cognition, greater motor severity and a postural-instability/gait-difficulty phenotype predicted cognitive decline or mortality. In a separate series of 100 autopsy-confirmed cases, earlier autonomic dysfunction was associated with earlier disability milestones and shorter survival; older age at diagnosis and poorer initial levodopa responsiveness also predicted shorter survival. These are group-level associations, not individual schedules. Moreover, motor phenotypes can change: a 396-patient longitudinal study found that baseline tremor-dominant classification did not reliably predict subsequent progression, cautioning against treating clinical subtypes as permanent prognostic categories. (pmc.ncbi.nlm.nih.gov)

Symptomatic pharmacological treatment

Levodopa remains the principal treatment for motor symptoms, with greater symptomatic efficacy than dopamine agonists or monoamine oxidase-B (MAO-B) inhibitors. Its clinical development accelerated during the 1960s, including George Cotzias and colleagues’ 1967 study of oral dopa treatment and subsequent trials of L-dopa. Unlike dopamine, levodopa crosses the blood–brain barrier; aromatic L-amino-acid decarboxylase then converts it into dopamine in the brain. It is ordinarily combined with carbidopa or benserazide, which inhibit peripheral conversion, increasing the amount available to the brain and reducing peripheral adverse effects such as nausea. These treatments relieve symptoms but have not established a disease-modifying effect. The American Academy of Neurology’s 2021 guideline favoured levodopa as initial dopaminergic therapy for most people seeking treatment of early motor symptoms. (nejm.org)

Levodopa can produce nausea, orthostatic hypotension, hallucinations and involuntary movements, or dyskinesia. With disease progression, benefit may no longer last until the next dose: this end-of-dose “wearing off” creates periods of reduced mobility, termed “off” time, alternating with “on” periods of effective symptom control. Pharmacological management includes adjustment of levodopa timing and addition of drugs that prolong or supplement its action. This involves a trade-off: increasing dopaminergic exposure can reduce off time while aggravating dyskinesia or hallucinations. NICE’s 2017 guideline identified dopamine agonists, MAO-B inhibitors and catechol-O-methyltransferase (COMT) inhibitors as adjunctive options when fluctuations persist despite optimized levodopa treatment. (ninds.nih.gov)

Dopamine agonists directly stimulate dopamine receptors rather than requiring conversion into dopamine. Examples include oral pramipexole and ropinirole, transdermal rotigotine, and injectable apomorphine, which can provide rescue treatment for off episodes. Agonists can be used alone in selected early cases or alongside levodopa, but generally provide less motor improvement than levodopa. Important adverse effects include nausea, hypotension, peripheral oedema, hallucinations, excessive daytime sleepiness and sudden sleep onset. Their particularly important behavioural complications are impulse-control disorders, including compulsive gambling, shopping, eating and sexual behaviour. Cognitive impairment, pre-existing hallucinations and older age constrain their use; the 2021 AAN guideline specifically discouraged initial agonist treatment in people over 70 and other groups at increased risk of adverse effects. (ninds.nih.gov)

MAO-B inhibitors—selegiline, rasagiline and safinamide—reduce dopamine breakdown in the brain. Selegiline and rasagiline may treat relatively mild early symptoms, while these agents also serve as levodopa adjuncts; adverse effects include nausea, insomnia and orthostatic hypotension. COMT inhibitors, including entacapone, opicapone and tolcapone, prolong levodopa action by inhibiting its metabolism. Entacapone acts in peripheral tissues and is used with levodopa rather than as independent antiparkinsonian treatment. Adverse effects include increased dyskinesia, diarrhoea and urine discoloration; tolcapone additionally carries a risk of severe liver injury. Anticholinergics such as trihexyphenidyl and benztropine have a narrower role, principally against tremor, because dry mouth, constipation, urinary retention, blurred vision, confusion and memory impairment limit tolerability. (ninds.nih.gov)

Amantadine is particularly useful against levodopa-induced dyskinesia. It is a weak NMDA-receptor antagonist, although its therapeutic mechanism is not fully established. Extended-release amantadine also reduces off time: two placebo-controlled trials in its prescribing information reported approximately 0.9 and 1.1 fewer daily off hours relative to placebo. Hallucinations, dizziness, peripheral oedema and livedo reticularis—a mottled skin discoloration—are important adverse effects. Because amantadine is predominantly excreted unchanged in urine, renal impairment increases exposure and requires formulation-specific dose adjustment. (accessdata.fda.gov)

Newer levodopa delivery systems seek to sustain drug exposure rather than alter the underlying disease. Extended-release oral carbidopa–levodopa formulations, including Crexont, combine release characteristics to extend symptomatic benefit between doses. Enteral carbidopa–levodopa suspension, approved in the United States as Duopa in January 2015, provides a 16-hour infusion into the jejunum, bypassing gastric delivery. Foscarbidopa–foslevodopa, approved as Vyalev on October 16, 2024, uses soluble prodrugs for continuous subcutaneous infusion. Its 12-week randomized trial showed an adjusted reduction in daily off time 1.79 hours greater than immediate-release oral carbidopa–levodopa. Subcutaneous delivery avoids an intestinal tube but introduces infusion-site reactions and infections; device management and selection for continuous therapies are addressed separately. (accessdata.fda.gov)

Advanced and surgical therapies

Deep brain stimulation (DBS) delivers electrical pulses through implanted electrodes, usually placed bilaterally in the subthalamic nucleus (STN) or internal globus pallidus (GPi), and connected to a programmable pulse generator beneath the skin of the chest. Stimulation modifies abnormal activity in motor circuits rather than replacing lost dopamine neurons. Its adjustable settings distinguish it from procedures that permanently destroy tissue. Both targets improve tremor, rigidity, bradykinesia and motor fluctuations. STN stimulation generally permits greater reductions in dopaminergic medication; GPi stimulation can suppress dyskinesia without requiring substantial medication reduction and may be selected when cognitive or depressive adverse effects are a particular concern. Neither target arrests disease progression. (ninds.nih.gov)

DBS candidacy depends on the pattern of disability, not simply disease duration or a designation of “advanced” disease. Typical candidates have disabling “off” periods, troublesome dyskinesia or medication-resistant tremor despite optimized drug treatment. Levodopa responsiveness helps identify symptoms likely to improve, although resistant tremor can respond even when medication does not adequately suppress it. Established dementia, significant uncontrolled psychiatric illness and substantial surgical risk generally limit eligibility; levodopa-resistant balance impairment, speech difficulties and freezing are less reliably improved. Assessment involves movement-disorder neurology, functional neurosurgery and neuropsychology, with evaluation of cognition, psychiatric status, medication response and realistic treatment goals. Postoperative programming and medication adjustment commonly require several months. (pubmed.ncbi.nlm.nih.gov)

Benefits and risks are illustrated by the 2009 randomized controlled trial led by Frances Weaver: at six months, patients receiving bilateral DBS gained approximately 4.6 hours per day of “on” time without troublesome dyskinesia, compared with essentially no gain under best medical therapy. DBS also improved motor function and quality of life, but serious adverse events were more frequent. Procedural risks include intracranial hemorrhage and infection; implanted systems can develop lead or other hardware problems. Stimulation may worsen speech, gait or selected cognitive and psychiatric functions, sometimes requiring reprogramming. Continuing follow-up includes device checks, battery replacement or recharging, and reassessment as symptoms evolve. (vivo.weill.cornell.edu)

Continuous infusion offers an alternative device-assisted approach to motor fluctuations. Levodopa–carbidopa intestinal gel is delivered by a portable pump into the jejunum through a gastrostomy tube with a jejunal extension. In C. Warren Olanow and colleagues’ 2014 double-blind trial, daily “off” time fell by 4.04 hours with intestinal infusion versus 2.14 hours with immediate-release oral levodopa–carbidopa over 12 weeks. Tube blockage or displacement can interrupt treatment, while insertion and gastrointestinal complications include infection, obstruction and perforation. Subcutaneous alternatives include continuous apomorphine infusion and foslevodopa–foscarbidopa infusion; the latter provides 24-hour pump delivery without an intestinal tube but carries risks of infusion-site reactions, infection, hallucinations and dyskinesia. These treatments require dose titration, equipment training and ongoing support. (pubmed.ncbi.nlm.nih.gov)

Lesion procedures historically included pallidotomy, targeting the globus pallidus, and thalamotomy, principally targeting tremor. Their irreversible tissue destruction contributed to their replacement by adjustable DBS in many settings. Focused ultrasound creates a thermal lesion by concentrating ultrasound energy through the skull under magnetic resonance imaging guidance, without an intracranial electrode or implanted generator. In Vibhor Krishna and colleagues’ 2023 sham-controlled pallidotomy trial, 69% of assessed treated patients versus 32% of controls met the three-month response criterion: at least a three-point improvement in treated-side motor impairment or dyskinesia. Adverse events included dysarthria, gait disturbance, visual disturbance and facial weakness. (ninds.nih.gov)

Focused-ultrasound indications are procedure- and jurisdiction-specific. The US Food and Drug Administration approved unilateral ultrasound pallidotomy for selected patients with medication-refractory motor complications on October 29, 2021. On July 3, 2025, it approved pallidothalamic tractotomy, including staged treatment of the opposite side at least six months after the first procedure, for eligible patients aged 30 or older. Such authorization does not make different lesion targets interchangeable: specialist assessment must establish the symptom target, anatomical accessibility and suitability for irreversible ablation, including the risks to speech, swallowing and gait. (accessdata.fda.gov)

Disease-modifying research and trials

Immunotherapies targeting alpha-synuclein aim to reduce pathological protein accumulation or its transmission between cells, rather than replace depleted dopamine. Prasinezumab and cinpanemab are monoclonal antibodies developed to bind alpha-synuclein, particularly aggregated forms. Neither antibody met its primary clinical efficacy endpoint in the phase II PASADENA and SPARK trials published in 2022; SPARK enrolled 357 participants and found no benefit from cinpanemab on clinical or dopamine-transporter imaging measures. These results did not establish that the target was irrelevant: the SPARK investigators could not verify clearance of pathological alpha-synuclein, and extracellular targeting might be insufficient to affect intracellular pathology. (nejm.org) The subsequent 586-participant PADOVA trial of prasinezumab also missed its primary endpoint of time to confirmed motor progression: the hazard ratio was 0.84, with $p=0.0657$. Exploratory findings supported continued investigation, but did not establish efficacy; the phase III PARAISO trial was ongoing in 2026. (roche.com)

Genetically informed approaches target LRRK2 kinase activity and GBA1-associated lysosomal dysfunction. BIIB122, an oral LRRK2 inhibitor, was tested in the phase IIb LUMA randomized controlled trial, involving 648 participants treated for 48–144 weeks. On May 21, 2026, its developers reported no benefit on primary or secondary clinical endpoints, despite substantial peripheral kinase inhibition and reduced phosphorylated Rab10 in a cerebrospinal fluid substudy. Development for idiopathic disease was discontinued, while the phase IIa BEACON study in pathogenic LRRK2-variant carriers continued. (sec.gov) GBA-directed research includes ambroxol, a pharmacological chaperone intended to improve glucocerebrosidase function; the 2026 ASPro-PD phase III protocol specified 330 participants with documented GBA1 status. Conversely, venglustat, which reduces glucosylceramide synthesis, failed to provide clinical benefit in its phase II trial in GBA1-associated disease. (pubmed.ncbi.nlm.nih.gov)

Repurposed metabolic drugs have been investigated for effects on neuronal survival, insulin signalling and inflammation. Exenatide, a GLP-1 receptor agonist used for diabetes, produced encouraging results in smaller studies, but the 2025 phase III Exenatide-PD3 trial did not confirm them. Among 194 participants receiving weekly exenatide or placebo for 96 weeks, off-medication motor scores worsened by 5.7 and 4.5 points, respectively, without a significant treatment difference. Clinical and imaging outcomes provided no evidence of disease modification. The investigators identified uncertainties about effective brain exposure and target engagement; neither a specific biological explanation for failure nor a responsive subgroup was established. (discovery.ucl.ac.uk) NLY01, a modified exenatide intended to attenuate microglial activation, likewise failed to improve the primary outcome in a 255-participant, 36-week trial published in 2024. Thus, the proposed anti-inflammatory mechanism remained unsupported by clinical efficacy in that study. (pubmed.ncbi.nlm.nih.gov)

Nicotinamide riboside is being studied as a precursor of nicotinamide adenine dinucleotide (NAD), a cofactor involved in cellular energy metabolism. The 2022 NADPARK phase I trial randomized 30 newly diagnosed, untreated participants to 1,000 mg daily or placebo for 30 days. Treatment increased cerebral NAD levels variably and altered metabolic measures, with exploratory clinical improvements among participants showing increased brain NAD. The study established short-term biological activity, not slowed neurodegeneration: its small sample and brief duration could not demonstrate an effect on long-term progression. This distinction between biomarker responses and clinical disease modification is central to interpreting early neuroprotective trials. (sciencedirect.com)

Cell replacement programmes transplant dopamine-producing progenitors into the putamen to reconstruct local dopaminergic function. Viviane Tabar and colleagues reported a 12-participant, open-label phase I bemdaneprocel study in 2025, using human embryonic stem-cell-derived progenitors; a separate Kyoto phase I/II study used induced pluripotent stem-cell-derived cells in seven participants. These studies assessed safety and demonstrated imaging evidence consistent with graft survival, but their uncontrolled designs could not establish efficacy. (nature.com) Bemdaneprocel entered the sham-surgery-controlled phase III exPDite-2 trial in September 2025. In Japan, raguneprocel received conditional, time-limited approval on March 6, 2026, for improving motor symptoms inadequately controlled by existing medication, with post-marketing evidence required for full approval—not an authorization based on demonstrated arrest of neurodegeneration. (bayer.com)

Gene therapy programmes distinguish restoration of dopamine handling from protection of surviving neurons. AAV2-mediated delivery of aromatic L-amino acid decarboxylase increases the putamen’s capacity to convert levodopa into dopamine; phase I studies demonstrated increased enzyme activity but did not establish slowed disease progression. (pmc.ncbi.nlm.nih.gov) AB-1005 instead delivers the gene for glial cell line-derived neurotrophic factor, intended to support dopaminergic neurons. Its randomized, sham-surgery-controlled phase II REGENERATE-PD programme was underway in 2026, testing whether sustained local growth-factor production yields clinical benefit beyond the safety findings of earlier studies. (bayer.com)

Non-motor and multidisciplinary care

Long-term care combines neurological review with nursing, rehabilitation, psychological care and social support. Neurologists assess progression and distinguish disease-related symptoms from medication effects; Parkinson’s specialist nurses provide continuing contact, monitor treatment and coordinate referrals. NICE’s 2017 guideline specifies an agreed care plan, accessible specialist services and regular access to clinical monitoring and medication adjustment. Occupational therapists address difficulties with dressing, bathing, food preparation and employment, while speech and language therapists assess communication, swallowing and saliva control. These services have distinct functions rather than serving merely as adjuncts to dopaminergic treatment. (nice.org.uk)

Treatment of depression includes antidepressants and Parkinson’s-adapted cognitive behavioral therapy (CBT). In a 2012 randomized trial involving 115 participants, paroxetine, which inhibits serotonin reuptake, and extended-release venlafaxine, which inhibits serotonin and norepinephrine reuptake, reduced depressive symptoms over 12 weeks without worsening motor function. A separate 2011 trial led by Roseanne Dobkin assigned 80 participants to ten weeks of adapted CBT or clinical monitoring: treatment-response rates were 56% and 8%, respectively. For established Parkinson’s disease dementia, rivastigmine inhibits cholinesterases to enhance cholinergic transmission. Its pivotal 2004 trial enrolled 541 patients and found modest cognitive and global clinical benefits over 24 weeks, accompanied by higher rates of nausea, vomiting and tremor. These results concern dementia, not all forms of mild cognitive impairment. (pubmed.ncbi.nlm.nih.gov)

Sleep and autonomic management begins with assessment of contributing illnesses and medication effects. NICE identifies melatonin or clonazepam as treatment options for rapid eye movement sleep behavior disorder after review of possible pharmacological causes; modafinil is considered for excessive daytime sleepiness only after reversible causes have been excluded. For orthostatic hypotension, management includes reviewing medicines that lower blood pressure; midodrine can increase vascular tone but requires monitoring for hypertension while lying down. The German Society of Neurology’s guideline describes non-drug measures including adequate fluid intake and abdominal compression. Constipation management combines appropriately tolerated dietary fiber and fluids with agents such as macrogol, an osmotic laxative that retains water in the bowel. Drug choice must account for interactions among symptoms—for example, the cognitive effects of anticholinergic medicines used for bladder problems. (nice.org.uk)

Physiotherapy and exercise-based programs target functional limitations through aerobic conditioning, resistance exercise, balance training and task-specific practice. The American Physical Therapy Association’s 2022 guideline supports external cueing: auditory rhythms, visual targets or somatosensory signals provide explicit timing or spatial information for movement and can improve gait performance. Speech treatment likewise uses structured practice rather than medication alone. In the 2024 PD COMM randomized trial of 388 people, Lee Silverman Voice Treatment (LSVT LOUD)—four 50-minute sessions weekly for four weeks, with home practice—reduced the self-reported Voice Handicap Index by 8.0 points relative to no speech therapy at three months. Vocal strain was the predominant reported adverse event. Swallowing therapy has a separate safety objective: improving swallowing efficiency and reducing aspiration risk, with techniques including expiratory muscle strength training. (pmc.ncbi.nlm.nih.gov)

Palliative care can accompany active neurological treatment rather than being restricted to the final days of life. It addresses symptom burden, psychological and spiritual distress, caregiver needs and advance care planning. Planning may document treatment preferences and identify a surrogate decision-maker before communication or cognition deteriorates; practical support includes personal care, equipment and respite services. In Benzi Kluger and colleagues’ 2020 randomized trial, 210 patients with Parkinson’s disease or related disorders and 175 caregivers participated in standard care or standard care supplemented by an outpatient palliative team. The team included a neurologist, nurse, social worker and chaplain, with specialist palliative-medicine input. Patient quality of life improved relative to standard care at six months; caregiver burden did not differ significantly at that primary endpoint, although a benefit was observed at twelve months. (nice.org.uk)

Discovery and history of research

In 1817, the London surgeon and apothecary James Parkinson published An Essay on the Shaking Palsy, describing six cases of the condition he called paralysis agitans. Some observations came from encounters in the street rather than detailed examinations; one man was observed only at a distance. Parkinson nevertheless brought together resting tremor, a forward-bent posture, progressive difficulty moving, and a tendency for walking to accelerate into running. His account also recorded constipation, disturbed sleep, and difficulties with speech and swallowing. He stated that intellect remained unaffected and proposed a lesion in the upper spinal cord—features of his interpretation that later research revised. The essay established a recognizable clinical syndrome without identifying its underlying pathology. (gutenberg.org)

During the later nineteenth century, Jean-Martin Charcot and his students at the Salpêtrière Hospital in Paris refined the syndrome through systematic clinical observation. In lectures published in 1872, Charcot distinguished slowness of movement from muscular weakness and from the mechanical restriction caused by rigidity. He separated the resting tremor associated with Parkinson’s syndrome from the action-related tremor of multiple sclerosis, and recognized both tremulous and predominantly rigid–akinetic presentations. Charcot advocated naming the condition after Parkinson rather than retaining “shaking palsy”: patients were not necessarily paralysed, and some had no tremor. His teaching helped establish Parkinson’s disease as a distinct neurological diagnosis. (pmc.ncbi.nlm.nih.gov)

Microscopic and anatomical discoveries followed. In 1912, Friedrich Heinrich Lewy described intracellular inclusions in affected brains, initially in regions outside the substantia nigra. In 1919, Konstantin Tretiakoff reported these inclusions in the substantia nigra, named them Lewy bodies, and connected degeneration of this pigmented nucleus with parkinsonism. These observations supplied anatomical evidence beyond the nineteenth-century clinical descriptions, although the chemical composition of the inclusions and the functional consequences of nigral degeneration remained unresolved. (nature.com)

The neurochemical breakthrough began in the late 1950s. Arvid Carlsson and colleagues showed that reserpine, which depleted brain monoamines, produced profound immobility in experimental animals, and that administering the dopamine precursor levodopa restored movement. Their findings helped establish dopamine as a neurotransmitter in its own right rather than merely an intermediate in noradrenaline synthesis. In 1960, Herbert Ehringer and Oleh Hornykiewicz demonstrated severe dopamine depletion in the striatum of post-mortem brains from people with Parkinson’s disease. This supplied a biochemical rationale for replacement treatment: dopamine itself crosses the blood–brain barrier poorly, whereas levodopa can enter the brain and be converted to dopamine. (nobelprize.org)

In 1961, Hornykiewicz and Walther Birkmayer reported striking, though short-lived, improvements after intravenous levodopa administration. Practical long-term treatment emerged from George Cotzias’s work: his group reported sustained benefit with gradually increased oral D,L-dopa doses in 1967, followed by treatment with the physiologically active L-isomer. A 1969 report by Cotzias, Paul Papavasiliou, and Rosemary Gellene described 28 patients: improvement was rated marked in 10 and dramatic in another 10, and benefits were often sustained for up to two years. Slow dose escalation reduced nausea and vomiting, while involuntary movements revealed an important treatment complication. (pubmed.ncbi.nlm.nih.gov)

The dopamine discoveries received recognition in the 2000 Nobel Prize in Physiology or Medicine, shared by Carlsson, Paul Greengard, and Eric Kandel for discoveries concerning signal transduction in the nervous system. Carlsson’s contribution concerned dopamine’s transmitter function and its importance for movement; Greengard investigated intracellular responses to neurotransmitters, while Kandel studied mechanisms underlying learning and memory. The award therefore recognized a broader foundation of neuroscience, within which the experimental basis of dopamine replacement for Parkinson’s disease was a major clinical consequence. (nobelprize.org)

Experimental models and research tools

Toxin-based models produce experimentally controlled damage to the nigrostriatal dopamine system. In 1968, Urban Ungerstedt demonstrated that intracerebral 6-hydroxydopamine (6-OHDA) caused degeneration of dopamine and noradrenaline neurons; injection into the substantia nigra damaged the nigrostriatal pathway and produced marked motor disturbances. Because 6-OHDA does not readily cross the blood–brain barrier, animal models require direct brain injection. MPTP, by contrast, crosses the barrier and is metabolized to the toxic pyridinium compound $\mathrm{MPP}^{+}$, which inhibits mitochondrial complex I and compromises energy production. These systems provide defined lesions for investigating neuronal injury and testing restoration of dopaminergic function. Their imposed toxic insult, however, models a particular injury mechanism rather than the full sequence of slowly developing human disease. (sciencedirect.com)

Genetically engineered animals allow investigators to manipulate disease-associated proteins independently of toxin exposure. In 2000, Eliezer Masliah and colleagues reported that mice expressing human alpha-synuclein developed neuronal inclusions, loss of dopaminergic terminals and motor impairment. Such experiments connect protein expression with cellular and behavioural consequences, but their findings depend on the expression pattern and genetic construct. Preformed-fibril models instead introduce assembled alpha-synuclein into animals or cultured neurons to initiate aggregation of endogenous protein. In Kelvin Luk and colleagues’ 2012 study, a single striatal injection of synthetic fibrils into wild-type mice produced Lewy-like pathology in interconnected brain regions, followed by nigral dopaminergic neuron loss and motor deficits. This provides a system for examining seeded aggregation and spread without requiring a human transgene; the experimental inoculation does not itself establish how aggregation begins spontaneously in patients. (pubmed.ncbi.nlm.nih.gov)

Patient-derived induced pluripotent stem cells (iPSCs) preserve a donor’s genetic background while supplying renewable human cells for differentiation into neurons. A 2016 study by Susanne Holmqvist and colleagues established a library from patients carrying several Parkinson-associated mutations, using reprogrammed skin fibroblasts. Three-dimensional midbrain organoids extend this approach by generating tissue-like structures containing dopaminergic neurons and neuronal networks. In a 2019 study of LRRK2-G2019S organoids, investigators measured dopaminergic differentiation and network branching at 10, 35 and 70 days, alongside genetically matched controls in which the mutation had been introduced or corrected. Some abnormalities tracked the mutation, whereas others persisted after correction, illustrating why donor background and isogenic controls matter when attributing a cellular phenotype to one variant. (nature.com)

Cellular age is an important limitation of iPSC systems: reprogramming can erase age-associated features, making late-onset degeneration difficult to reproduce. In 2013, Justine Miller and colleagues used expression of progerin, an altered nuclear-lamina protein, to induce aging-related changes in iPSC-derived dopaminergic neurons and reveal Parkinson-related phenotypes. This experimentally imposed aging condition enables investigation of age-dependent vulnerability, but is distinct from ordinary aging. Human-cell platforms also permit controlled toxicity experiments: a 2022 study combined three-dimensional neuronal cultures with an endothelial barrier and compared responses to MPTP, $\mathrm{MPP}^{+}$ and 6-OHDA, linking barrier passage with neuronal morphology and mitochondrial activity. (pubmed.ncbi.nlm.nih.gov)

Longitudinal cohorts and biobanks connect laboratory measurements to clinical trajectories. The Parkinson’s Progression Markers Initiative (PPMI), launched in 2010, combines repeated clinical assessments, imaging, genetic information and standardized biospecimen collection, including blood and cerebrospinal fluid, to support biomarker research. Its shared datasets also support machine-learning analyses of disease heterogeneity. In 2021, Kristen Severson and colleagues modelled up to seven years of observations from 423 patients with early disease and 196 controls, identifying eight statistical disease states differentiated chiefly by functional impairment, tremor, bradykinesia and neuropsychiatric measures. Validation used an independent cohort of 610 patients from the Parkinson’s Disease Biomarkers Program. The resulting trajectories overlapped and were not strictly sequential, indicating that these model-derived states describe changing clinical patterns rather than fixed biological subtypes. (blog.ppmi-info.org)

Public health, economics and social impact

The economic burden extends beyond treatment expenditure to lost employment, unpaid care and adaptations needed for daily living. A US cost-of-illness study published by Grace Yang and colleagues in 2020 estimated that approximately 1.04 million people had diagnosed Parkinson’s disease in 2017, with an annual economic burden of US$51.9 billion in that year’s dollars. Direct medical costs accounted for $25.4 billion, while indirect and non-medical costs accounted for $26.5 billion. The latter included $14.2 billion in productivity-related losses affecting patients and caregivers, $7.5 billion in non-medical expenses, and $4.8 billion in disability-income payments. These categories capture different consequences for households and health systems: medical expenditure includes hospital and outpatient services, whereas non-medical expenditure includes paid assistance, transport and home modifications. The estimate’s inclusion of disability payments also distinguishes it from analyses restricted to healthcare spending or lost production. (nature.com)

Much long-term support is supplied by relatives and friends rather than paid services. Caregiving may involve assistance with washing, dressing, meals and mobility, administering medication, organizing appointments and responding to emergencies. A scoping review published in 2025 documented these responsibilities alongside emotional support and household financial management. (pmc.ncbi.nlm.nih.gov) A separate 2025 systematic review found that greater interference with activities of daily living, more severe neuropsychiatric symptoms, poorer patient quality of life and poorer caregiver mental health predicted greater caregiver burden. Thus, care demands are not adequately represented by motor impairment alone. (pubmed.ncbi.nlm.nih.gov) WHO identifies physical, emotional and financial pressures on informal carers, who may provide many hours of support each day. It also documents workplace discrimination and restricted community participation among people with Parkinson’s disease, adding social exclusion to the consequences of disability. (who.int)

Access inequalities persist even in countries with substantial healthcare resources. A study of US Medicare beneficiaries with Parkinson’s disease, using 2019 claims and published in 2023, found that 40% had no visit to a neurologist during that calendar year; only 9.1% visited a movement-disorders specialist. Specialist utilization was lower among women, several racial and ethnic minority groups, and rural residents. The analysis also examined physical, occupational and speech-language therapy and mental-health services, showing that access encompasses more than prescribing medication. These claims describe recorded service use rather than proving why an individual did not receive specialist care, but they provide a population-level measure of gaps that clinic-based studies can overlook. (nature.com)

In low- and middle-income countries, shortages of specialist services coexist with problems of medication availability and affordability. Levodopa/carbidopa is included on the WHO Model List of Essential Medicines, yet access is not universal. WHO identifies trained non-specialist workers in primary care as important providers where neurological services are unavailable. Its 2022 technical brief framed Parkinson’s disease as a public-health issue, linking treatment access, workforce capacity, education and support for carers. These priorities also fall within the Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders 2022–2031, endorsed by the World Health Assembly in May 2022. (who.int)

Patient organizations combine awareness campaigns with research funding and representation. World Parkinson’s Day began on April 11, 1997, through the European Parkinson’s Disease Association, now Parkinson’s Europe, with WHO co-sponsorship; the date commemorates James Parkinson’s birthday. Activities include public education, community events and fundraising. (parkinsonseurope.org) Research charities also channel substantial resources into scientific programmes: the Michael J. Fox Foundation reported 90 grants totalling more than US$309.1 million awarded in April and May 2024, including funding administered on behalf of the Aligning Science Across Parkinson’s initiative. The supported projects addressed disease biology, detection and treatment development, illustrating how organized philanthropy supplements public and commercial research funding. (michaeljfox.org)

Open questions and future directions

Selective neuronal vulnerability remains incompletely explained: neurons sharing the same neurotransmitter can differ markedly in their susceptibility to degeneration. In 2015, Consiglia Pacelli and colleagues found that cultured nigral dopamine neurons had more extensive axonal branching, higher basal mitochondrial oxidative phosphorylation, and less respiratory reserve than relatively resistant ventral tegmental neurons. Reducing axonal branching also reduced susceptibility to mitochondrial toxins, supporting an energy-demand hypothesis rather than demonstrating a complete explanation for human disease. In 2022, Tushar Kamath and colleagues analysed 22,048 human dopamine-neuron nuclear profiles and identified ten populations. A ventral substantia nigra population expressing SOX6 and AGTR1 was particularly depleted in Parkinson’s disease and enriched for expression of genes associated with inherited disease risk. These findings sharpen the question from why dopamine neurons die to why particular molecularly defined subpopulations die while neighbouring populations survive. (pubmed.ncbi.nlm.nih.gov)

Whether idiopathic and genetically associated disease converge on one obligatory pathway is also unresolved. Similar motor syndromes need not imply identical molecular pathology. Andrew Siderowf and colleagues’ 2023 Parkinson’s Progression Markers Initiative analysis found cerebrospinal-fluid α-synuclein seed-amplification positivity in 93.3% of sporadic cases, 95.9% of GBA-associated cases, but only 67.5% of LRRK2-associated cases. The study therefore provided evidence of biological heterogeneity within clinically diagnosed disease, although assay negativity alone does not establish a separate mechanism. The 2024 SynNeurGe research criteria explicitly accommodate partly overlapping pathogenic pathways by recording synuclein pathology, neurodegeneration, and genetic findings separately. A central research problem is determining which shared abnormalities are causal treatment targets and which represent downstream consequences of neuronal injury. (pubmed.ncbi.nlm.nih.gov)

Early biomarkers must establish more than discrimination between established disease and healthy controls. In the 2023 study of 1,123 participants, α-synuclein seed amplification had 87.7% sensitivity for Parkinson’s disease and 96.3% specificity against healthy controls; however, its cross-sectional design did not determine an individual’s time to clinical onset. That distinction matters when identifying people for preventive intervention. Candidate blood tests may make large-scale recruitment less invasive: a 2024 proteomic study reported an eight-protein panel that classified 79% of its pre-motor participants as Parkinson-like, with samples extending up to seven years before motor onset. Such results require prospective validation beyond enriched research cohorts, including assessment of false-positive findings and whether repeated measurements predict clinical progression rather than merely biological abnormality. (pubmed.ncbi.nlm.nih.gov)

Preventive trials are beginning to test the feasibility of intervening before conventional motor diagnosis. The 2026 Slow-SPEED protocol describes three randomised trials of remotely delivered exercise against active controls, targeting isolated REM sleep behaviour disorder in the Netherlands, hyposmia in the United Kingdom, and LRRK2/GBA1 variant carriers in the United States. Planned sample sizes are 110, 110, and 600, respectively, with interventions lasting 18–36 months. These are feasibility and preliminary-efficacy studies, not evidence that exercise prevents Parkinson’s disease. Their differing entry criteria illustrate an unresolved design problem: genetic susceptibility, prodromal symptoms, and molecular pathology identify overlapping but non-equivalent populations, whose progression rates and appropriate trial endpoints may differ. (pubmed.ncbi.nlm.nih.gov)

Biological subtyping offers a route toward more precisely targeted trials, but alternative frameworks embody different disease boundaries. In 2024, Tanya Simuni and colleagues proposed the neuronal α-synuclein disease integrated staging system, combining pathological α-synuclein, dopaminergic dysfunction, and functional impairment; its earliest stages include individuals without clinical signs or symptoms. SynNeurGe instead classifies synuclein pathology, neurodegeneration, and pathogenic genetic variants as distinct dimensions. Both were proposed for research rather than routine clinical diagnosis. For personalised treatment, the crucial validation step is not simply showing that a subtype has a different prognosis: it is demonstrating that subtype membership predicts a reproducibly different response to a mechanism-directed intervention. (sciencedirect.com)

References

1. Parkinson's Diseaseninds.nih.gov
2. Parkinson’s Disease and Parkinsonism: Neuropathologypmc.ncbi.nlm.nih.gov
3. MDS clinical diagnostic criteria for Parkinson's diseasepubmed.ncbi.nlm.nih.gov
4. Secondary parkinsonism: MedlinePlus Medical Encyclopediamedlineplus.gov
5. Parkinson's Diseaseninds.nih.gov
6. Convection-Enhanced Delivery to Study the Pathophysiology Underlying the Clinical Features of Parkinson s Diseaseninds.nih.gov
7. Lewy Body Disorderspmc.ncbi.nlm.nih.gov
8. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortiumpmc.ncbi.nlm.nih.gov
9. Lewy Body Dementia: Causes, Symptoms, and Diagnosisnia.nih.gov
10. Parkinson’s Disease: Causes, Symptoms, and Treatmentsnia.nih.gov
11. MDS Clinical Diagnostic Criteria for Parkinson's Diseasefile.medtrib.cn
12. 1: Parkinson's disease - clinical presentation, diagnosis and stagingncbi.nlm.nih.gov
13. The effect of doorway characteristics on freezing of gait in Parkinson’s diseasepmc.ncbi.nlm.nih.gov
14. How stable are Parkinson's disease subtypes in de novo patients: Analysis of the PPMI cohort?pubmed.ncbi.nlm.nih.gov
15. Motor phenotype classification in moderate to advanced PD in BioFIND studypubmed.ncbi.nlm.nih.gov
16. The onset of nonmotor symptoms in Parkinson's disease (the ONSET PD study)pubmed.ncbi.nlm.nih.gov
17. Delineating nonmotor symptoms in early Parkinson's disease and first-degree relativespubmed.ncbi.nlm.nih.gov
18. REM sleep behaviour disorderpubmed.ncbi.nlm.nih.gov
19. Pharmacological management of non-motor symptomsncbi.nlm.nih.gov
20. Autonomic Dysfunction in Parkinson's Diseasepubmed.ncbi.nlm.nih.gov
21. Association of transient orthostatic hypotension with falls and syncope in patients with Parkinson diseasepubmed.ncbi.nlm.nih.gov
22. Dissociating apathy and depression in Parkinson diseasepubmed.ncbi.nlm.nih.gov
23. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's diseasepubmed.ncbi.nlm.nih.gov
24. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patientspubmed.ncbi.nlm.nih.gov
25. Impulse control and related disorders in Parkinson's diseasepubmed.ncbi.nlm.nih.gov
26. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's diseasepubmed.ncbi.nlm.nih.gov
27. Disease duration and the integrity of the nigrostriatal system in Parkinson's diseasepubmed.ncbi.nlm.nih.gov
28. Parkinson’s Disease: Etiology, Neuropathology, and Pathogenesisncbi.nlm.nih.gov
29. Neuropathology and molecular diagnosis of Synucleinopathiespmc.ncbi.nlm.nih.gov
30. α-Synuclein in Lewy bodiesnature.com
31. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodiespubmed.ncbi.nlm.nih.gov
32. Lewy pathology in Parkinson's disease consists of crowded organelles and lipid membranespubmed.ncbi.nlm.nih.gov
33. Staging of brain pathology related to sporadic Parkinson's diseasepubmed.ncbi.nlm.nih.gov
34. Neuropathological Staging of Brain Pathology in Sporadic Parkinson's disease: Separating the Wheat from the Chaffpubmed.ncbi.nlm.nih.gov
35. Unified Staging System for Lewy Body Disorders: Correlation with Nigrostriatal Degeneration, Cognitive Impairment and Motor Dysfunctionpmc.ncbi.nlm.nih.gov
36. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's diseasepubmed.ncbi.nlm.nih.gov
37. Circuits within the Basal Ganglia Systemncbi.nlm.nih.gov
38. Lesion to the nigrostriatal dopamine system disrupts stimulus-response habit formationpubmed.ncbi.nlm.nih.gov
39. A Neural Substrate of Prediction and Rewardweb.math.princeton.edu
40. Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitrynature.com
41. Concurrent activation of striatal direct and indirect pathways during action initiationpubmed.ncbi.nlm.nih.gov
42. Reduction in subthalamic 8-35 Hz oscillatory activity correlates with clinical improvement in Parkinson's diseasepubmed.ncbi.nlm.nih.gov
43. DailyMed — CARBIDOPA AND LEVODOPA tabletdailymed.nlm.nih.gov
44. DailyMed — PRAMIPEXOLE DIHYDROCHLORIDE tablet, extended releasedailymed.nlm.nih.gov
45. Evaluation of the noradrenergic system in Parkinson's disease: an 11C-MeNER PET and neuromelanin MRI studypubmed.ncbi.nlm.nih.gov
46. Clinical correlates of raphe serotonergic dysfunction in early Parkinson's diseasepubmed.ncbi.nlm.nih.gov
47. Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunctionpubmed.ncbi.nlm.nih.gov
48. Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structurespubmed.ncbi.nlm.nih.gov
49. Structural and Dynamical Insights into the Membrane-Bound α-Synucleinpmc.ncbi.nlm.nih.gov
50. α-Synuclein Promotes SNARE-Complex Assembly in Vivo and in Vitrocbdm.hms.harvard.edu
51. α-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formationpmc.ncbi.nlm.nih.gov
52. Structural basis of membrane disruption and cellular toxicity by α-synuclein oligomerspubmed.ncbi.nlm.nih.gov
53. Pathological α-Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Non-transgenic Micepmc.ncbi.nlm.nih.gov
54. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagationpubmed.ncbi.nlm.nih.gov
55. alpha-Synuclein is phosphorylated in synucleinopathy lesions.pubmed.ncbi.nlm.nih.gov
56. Alpha-synuclein aggregates are phosphatase resistantpmc.ncbi.nlm.nih.gov
57. α-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicitypubmed.ncbi.nlm.nih.gov
58. Physiological C-terminal truncation of α-synuclein potentiates the prion-like formation of pathological inclusionspmc.ncbi.nlm.nih.gov
59. Mitochondrial complex I deficiency in Parkinson's diseasepubmed.ncbi.nlm.nih.gov
60. Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s diseasepmc.ncbi.nlm.nih.gov
61. Mitochondrial processing peptidase regulates PINK1 processing, import and Parkin recruitmentpubmed.ncbi.nlm.nih.gov
62. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagypubmed.ncbi.nlm.nih.gov
63. Gaucher’s Disease Glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathiespmc.ncbi.nlm.nih.gov
64. Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in micepubmed.ncbi.nlm.nih.gov
65. T cells of Parkinson’s disease patients recognize α-synuclein peptidespmc.ncbi.nlm.nih.gov
66. Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Diseasepmc.ncbi.nlm.nih.gov
67. Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson's Diseasepubmed.ncbi.nlm.nih.gov
68. Monogenic Parkinson Disease Overviewncbi.nlm.nih.gov
69. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.pubmed.ncbi.nlm.nih.gov
70. alpha-Synuclein locus triplication causes Parkinson's disease.pubmed.ncbi.nlm.nih.gov
71. LRRK2-Related Parkinson Diseasencbi.nlm.nih.gov
72. PRKN-Related Early-Onset Parkinson Diseasencbi.nlm.nih.gov
73. Monogenic Parkinson Disease Overviewncbi.nlm.nih.gov
74. Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: a meta-genome wide association studypmc.ncbi.nlm.nih.gov
75. Parkinson's disease variant detection and disclosure: PD GENEration, a North American study.pubmed.ncbi.nlm.nih.gov
76. PPMI Clinical Protocol, February 1, 2021ppmi-info.org
77. Rotenone, paraquat, and Parkinson's diseasepubmed.ncbi.nlm.nih.gov
78. Parkinson's Diseaseniehs.nih.gov
79. Risk of Parkinson Disease Among Service Members at Marine Corps Base Camp Lejeunepubmed.ncbi.nlm.nih.gov
80. Risk of Parkinson Disease Among Service Members at Marine Corps Base Camp Lejeunepmc.ncbi.nlm.nih.gov
81. Mild TBI and risk of Parkinson disease: A Chronic Effects of Neurotrauma Consortium Studypubmed.ncbi.nlm.nih.gov
82. Traffic-related air pollution, road traffic noise, and Parkinson's disease: Evaluations in two Dutch cohort studiespubmed.ncbi.nlm.nih.gov
83. Intake of dairy foods and risk of Parkinson diseasepubmed.ncbi.nlm.nih.gov
84. Caffeine intake, smoking, and risk of Parkinson disease in men and womenpubmed.ncbi.nlm.nih.gov
85. The prevalence of Parkinson's disease: a systematic review and meta-analysispubmed.ncbi.nlm.nih.gov
86. Incidence of Parkinson disease in North Americanature.com
87. Young-Onset Parkinson'sparkinson.org
88. Early-onset Parkinsonism and Early-onset Parkinson’s disease: A Population-based Study (2010–2015)pmc.ncbi.nlm.nih.gov
89. Global, regional, national epidemiology and trends of Parkinson’s disease from 1990 to 2021: findings from the Global Burden of Disease Study 2021pmc.ncbi.nlm.nih.gov
90. Parkinson diseasewho.int
91. MDS clinical diagnostic criteria for Parkinson's diseasemed.upenn.edu
92. Recommendations: Parkinson’s disease in adultsnice.org.uk
93. Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysispubmed.ncbi.nlm.nih.gov
94. DaTSCAN | European Medicines Agencyema.europa.eu
95. Assessment of heterogeneity among participants in the Parkinson’s Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional studypmc.ncbi.nlm.nih.gov
96. Assessment of heterogeneity among participants in the Parkinson’s Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional studydigitalcommons.library.tmc.edu
97. α-Synuclein Pathology in PRKN-Linked Parkinson's Disease: New Insights from a Blood-Based Seed Amplification Assaypubmed.ncbi.nlm.nih.gov
98. MDS Research Criteria for Prodromal Parkinson’s Diseasemed.stanford.edu
99. Update of the MDS research criteria for prodromal Parkinson's diseasepubmed.ncbi.nlm.nih.gov
100. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendationsmovementdisorders.org
101. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing resultsbumc.bu.edu
102. Medical Management and Prevention of Motor Complications in Parkinson’s Diseasepmc.ncbi.nlm.nih.gov
103. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestationspubmed.ncbi.nlm.nih.gov
104. Motor complications in Parkinson's disease: 13-year follow-up of the CamPaIGN cohortpubmed.ncbi.nlm.nih.gov
105. Motor Complications in Parkinson's Disease: Results from 3343 Patients Followed for up to 12 Yearspubmed.ncbi.nlm.nih.gov
106. 5-2-1 Criteria: A Simple Screening Tool for Identifying Advanced PD Patients Who Need an Optimization of Parkinson's Treatmentpubmed.ncbi.nlm.nih.gov
107. Long-Term Dementia Risk in Parkinson Diseasepmc.ncbi.nlm.nih.gov
108. Cognitive Impairment and Mortality in a Population-Based Parkinson’s Disease Cohortpmc.ncbi.nlm.nih.gov
109. Association of Autonomic Dysfunction With Disease Progression and Survival in Parkinson Diseasepubmed.ncbi.nlm.nih.gov
110. Postural instability and gait are associated with severity and prognosis of Parkinson diseasepubmed.ncbi.nlm.nih.gov
111. Experimental treatment of parkinsonism with L-Dopapubmed.ncbi.nlm.nih.gov
112. Comtan (entacapone tablets) prescribing informationaccessdata.fda.gov
113. Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summarypmc.ncbi.nlm.nih.gov
114. Entacapone Tablets, USP: Prescribing Informationdailymed.nlm.nih.gov
115. Gocovri prescribing informationaccessdata.fda.gov
116. Crexont prescribing informationaccessdata.fda.gov
117. Duopa prescribing informationaccessdata.fda.gov
118. Search Orphan Drug Designations and Approvals: Foscarbidopa and foslevodopaaccessdata.fda.gov
119. Vyalev prescribing informationaccessdata.fda.gov
120. Deep Brain Stimulation (DBS)ninds.nih.gov
121. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Subthalamic Nucleus and Globus Pallidus Internus Deep Brain Stimulation for the Treatment of Patients With Parkinson's Disease: Executive Summarypmc.ncbi.nlm.nih.gov
122. Parkinson’s Diseaseninds.nih.gov
123. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issuespubmed.ncbi.nlm.nih.gov
124. Deep Brain Stimulation for Parkinson Disease: An Expert Consensus and Review of Key Issuespmc.ncbi.nlm.nih.gov
125. Deep brain stimulation for Parkinson's disease: Recommendationsnice.org.uk
126. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trialvivo.weill.cornell.edu
127. Bilateral Deep Brain Stimulation vs Best Medical Therapy for Patients With Advanced Parkinson Disease: A Randomized Controlled Trialpmc.ncbi.nlm.nih.gov
128. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy studypubmed.ncbi.nlm.nih.gov
129. DUOPA prescribing informationaccessdata.fda.gov
130. Roche to advance prasinezumab into Phase III development for early-stage Parkinson's diseaseroche.com
131. PADOVA: A Phase IIb, Multicentre, Randomised, Double-blind, Placebo-Controlled Studymedically.roche.com
132. Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Diseasesec.gov
133. Protocol of ASPro-PD: a phase 3 trial of ambroxol to slow progression in genetically stratified Parkinson's diseasepubmed.ncbi.nlm.nih.gov
134. Safety and efficacy of venglustat in GBA1-associated Parkinson's diseasepubmed.ncbi.nlm.nih.gov
135. Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UKdiscovery.ucl.ac.uk
136. Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's diseasepubmed.ncbi.nlm.nih.gov
137. Phase I trial of hES cell-derived dopaminergic neurons for Parkinson’s diseasenature.com
138. Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson’s diseasenature.com
139. Quality statement 3: Referral to physiotherapy, occupational therapy or speech and language therapy | NICEnice.org.uk
140. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson diseasepubmed.ncbi.nlm.nih.gov
141. Cognitive-behavioral therapy for depression in Parkinson's disease: a randomized, controlled trialpubmed.ncbi.nlm.nih.gov
142. Diagnosis and treatment of autonomic failure, pain and sleep disturbances in Parkinson’s disease: guideline “Parkinson’s disease” of the German Society of Neurologypmc.ncbi.nlm.nih.gov
143. Physical Therapist Management of Parkinson Disease: A Clinical Practice Guideline From the American Physical Therapy Associationpmc.ncbi.nlm.nih.gov
144. Comparison of Integrated Outpatient Palliative Care With Standard Care in Patients With Parkinson Disease and Related Disorders: A Randomized Clinical Trialpubmed.ncbi.nlm.nih.gov
145. An Essay on the Shaking Palsygutenberg.org
146. The History of Parkinson's Disease: Early Clinical Descriptions and Neurological Therapiespmc.ncbi.nlm.nih.gov
147. 100 years of Lewy pathologynature.com
148. Milestones of Parkinson’s Disease Research: 200 Years of History and Beyondpmc.ncbi.nlm.nih.gov
149. Arvid Carlsson – Nobel Lecturenobelprize.org
150. A brief history of levodopapubmed.ncbi.nlm.nih.gov
151. The Nobel Prize in Physiology or Medicine, 1901–2000nobelprize.org
152. Transcript from an interview with Arvid Carlssonnobelprize.org
153. Nerve Signaling: Tracing the Wiring of Lifeeducationalgames.nobelprize.org
154. Human IPSC 3D brain model as a tool to study chemical-induced dopaminergic neuronal toxicitypmc.ncbi.nlm.nih.gov
155. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonismpubmed.ncbi.nlm.nih.gov
156. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridinepubmed.ncbi.nlm.nih.gov
157. The inhibition site of MPP+, the neurotoxic bioactivation product of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is near the Q-binding site of NADH dehydrogenasepubmed.ncbi.nlm.nih.gov
158. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorderspubmed.ncbi.nlm.nih.gov
159. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic micepubmed.ncbi.nlm.nih.gov
160. Creation of a library of induced pluripotent stem cells from Parkinsonian patientsnature.com
161. Modeling Parkinson’s disease in midbrain-like organoidsnature.com
162. Human iPSC-based modeling of late-onset disease via progerin-induced agingpubmed.ncbi.nlm.nih.gov
163. The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohortpmc.ncbi.nlm.nih.gov
164. Current and projected future economic burden of Parkinson’s disease in the U.S.nature.com
165. Parkinson’s Disease and Caregiving Roles, Demands, and Support Needs and Experiences: A Scoping Reviewpmc.ncbi.nlm.nih.gov
166. Predictors of Informal Caregiver Burden in Parkinson's Disease: A Systematic Reviewpubmed.ncbi.nlm.nih.gov
167. Parkinson diseasewho.int
168. Care access and utilization among medicare beneficiaries living with Parkinson’s diseasenature.com
169. Parkinson disease: a public health approach: technical briefwho.int
170. What We Fund: $309.1M Toward Disease Insights, Biomarker Advances and Drug Discoverymichaeljfox.org
171. Elevated Mitochondrial Bioenergetics and Axonal Arborization Size Are Key Contributors to the Vulnerability of Dopamine Neuronspubmed.ncbi.nlm.nih.gov
172. Single-cell genomic profiling of human dopamine neurons identifies a population that selectively degenerates in Parkinson’s diseasenature.com
173. Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional studypubmed.ncbi.nlm.nih.gov
174. Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study — author manuscriptescholarship.org
175. Plasma proteomics identify biomarkers predicting Parkinson’s disease up to 7 years before symptom onsetnature.com
176. Slow-SPEED: protocol for three randomised trials of remotely delivered exercise to prevent Parkinson's diseasepubmed.ncbi.nlm.nih.gov